Skip to Content
HCA HealthONE

Retatrutide is a new GLP-1 hit. But is it legal?

You've heard of the popular (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound), but there's a new kid on the block.

November 14, 2025
A woman stands on a scale to be weighed, in front of a hospital window.

A phase 3 clinical trial for retatrutide is currently underway and expected to wrap up in May 2026.After the trial is complete, the FDA usually takes 6 to 10 months to review the study once the results are submitted, says Michael Snyder, MD, the medical director of bariatric surgery at HCA HealthONE Rose in Denver, and an in-house obesity specialist at FuturHealth.

Read the MSN article.

Learn more about Dr. Snyder and the team at Denver Center for Bariatric Surgery.

Published:
November 14, 2025
Location:
HCA HealthONE Rose

Related Newsroom Articles

For weight loss, this intermittent fasting strategy beat out daily calorie counting
April 10, 2025
A new study found that a 4:3 intermittent fasting plan — with three days of fasting per week — helped people lose more weight than daily calorie counting.
For weight loss, this intermittent fasting strategy beat out daily calorie counting
April 10, 2025
A new study found that a 4:3 intermittent fasting plan — with three days of fasting per week — helped people lose more weight than daily calorie counting.